Denali Advisors LLC Has $112,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Denali Advisors LLC reduced its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 80.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,400 shares of the company's stock after selling 69,500 shares during the period. Denali Advisors LLC's holdings in Y-mAbs Therapeutics were worth $112,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its holdings in shares of Y-mAbs Therapeutics by 924.1% during the 1st quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company's stock valued at $30,000 after acquiring an additional 5,323 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Y-mAbs Therapeutics by 1,347.5% in the first quarter. Russell Investments Group Ltd. now owns 11,812 shares of the company's stock valued at $59,000 after purchasing an additional 10,996 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $67,000. Graham Capital Management L.P. purchased a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter worth about $68,000. Finally, Mariner LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $82,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on YMAB shares. HC Wainwright raised their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. Canaccord Genuity Group raised their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a report on Monday, March 4th. Wedbush reiterated an "outperform" rating and issued a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Finally, BMO Capital Markets raised their target price on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an "outperform" rating in a report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. According to MarketBeat, Y-mAbs Therapeutics has an average rating of "Hold" and a consensus price target of $16.57.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB traded down $0.07 during midday trading on Monday, reaching $16.19. The stock had a trading volume of 650,879 shares, compared to its average volume of 417,184. The stock has a market capitalization of $708.75 million, a P/E ratio of -33.04 and a beta of 0.75. Y-mAbs Therapeutics, Inc. has a 1-year low of $4.60 and a 1-year high of $20.90. The firm's fifty day simple moving average is $15.12 and its 200-day simple moving average is $9.31.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. The company had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. On average, equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In related news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the sale, the senior vice president now directly owns 33,889 shares of the company's stock, valued at approximately $560,185.17. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 21.50% of the stock is currently owned by corporate insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.